Spectral AI Announces DeepView SnapShot® M Moves Forward with Feedback from Brooke Army Medical Center Institute of Surgical Research
Spectral AI (NASDAQ: MDAI) announced progress on its DeepView SnapShot® M device following feedback from Brooke Army Medical Center and the U.S. Army Medical Research Institute. The device, supported by over $7.2 million in non-dilutive government funding since 2018, uses AI-powered multispectral imaging for rapid wound assessment in military settings. The technology received FDA Breakthrough Device Designation in 2018 and is trained on 340 billion clinically validated data points. The global mobile medical imaging market, valued at $14.78 billion in 2023, is projected to reach $18.4 billion by 2030.
Spectral AI (NASDAQ: MDAI) ha annunciato progressi sul suo dispositivo DeepView SnapShot® M in seguito ai feedback del Brooke Army Medical Center e del U.S. Army Medical Research Institute. Il dispositivo, sostenuto da oltre 7,2 milioni di dollari di finanziamenti governativi non diluitivi dal 2018, utilizza immagini multispettrali alimentate da intelligenza artificiale per una rapida valutazione delle ferite in contesti militari. La tecnologia ha ricevuto la Designazione di Dispositivo Innovativo della FDA nel 2018 ed è addestrata su 340 miliardi di punti dati clinicamente convalidati. Il mercato globale delle immagini mediche mobili, valutato 14,78 miliardi di dollari nel 2023, è previsto raggiungere 18,4 miliardi di dollari entro il 2030.
Spectral AI (NASDAQ: MDAI) anunció avances en su dispositivo DeepView SnapShot® M tras recibir comentarios del Brooke Army Medical Center y del U.S. Army Medical Research Institute. El dispositivo, respaldado por más de 7.2 millones de dólares en financiamiento gubernamental no dilutivo desde 2018, utiliza imágenes multispectrales impulsadas por inteligencia artificial para una rápida evaluación de heridas en entornos militares. La tecnología recibió la Designación de Dispositivo Innovador por parte de la FDA en 2018 y está entrenada con 340 mil millones de puntos de datos clínicamente validados. Se estima que el mercado global de imágenes médicas móviles, valorado en 14.78 mil millones de dólares en 2023, alcanzará 18.4 mil millones de dólares para 2030.
스펙트럴 AI (NASDAQ: MDAI)는 브룩 군 병원과 미국 육군 의학 연구소의 피드백을 바탕으로 DeepView SnapShot® M 장치의 발전을 발표했습니다. 이 장치는 2018년 이후로 720만 달러 이상의 비희석 정부 자금 지원을 받고 있으며, 군사 환경에서 신속한 상처 평가를 위해 AI 기반 멀티스펙트럼 이미징을 사용합니다. 이 기술은 2018년에 FDA 혁신 장치 지정을 받았으며, 3400억 개의 임상적으로 검증된 데이터 포인트로 훈련되었습니다. 2023년에는 147억 8천만 달러로 평가된 글로벌 이동식 의료 이미징 시장이 2030년에는 184억 달러에 이를 것으로 예상됩니다.
Spectral AI (NASDAQ: MDAI) a annoncé des progrès concernant son dispositif DeepView SnapShot® M suite aux retours du Brooke Army Medical Center et de l'U.S. Army Medical Research Institute. Le dispositif, soutenu par plus de 7,2 millions de dollars de financements gouvernementaux non dilutifs depuis 2018, utilise l'imagerie multispectrale alimentée par l'IA pour une évaluation rapide des blessures dans les contextes militaires. La technologie a reçu la désignation de Dispositif Innovant de la FDA en 2018 et est formée sur 340 milliards de points de données cliniquement validés. Le marché mondial de l'imagerie médicale mobile, évalué à 14,78 milliards de dollars en 2023, devrait atteindre 18,4 milliards de dollars d'ici 2030.
Spectral AI (NASDAQ: MDAI) hat Fortschritte bei seinem DeepView SnapShot® M-Gerät bekannt gegeben, nachdem Rückmeldungen vom Brooke Army Medical Center und dem U.S. Army Medical Research Institute erhalten wurden. Das Gerät, das seit 2018 mit mehr als 7,2 Millionen Dollar an nicht-dilutiven staatlichen Fördermitteln unterstützt wird, nutzt KI-gestützte multispektrale Bildgebung zur schnellen Wundbewertung in militärischen Umgebungen. Die Technologie erhielt 2018 die FDA Breakthrough Device Designation und ist mit 340 Milliarden klinisch validierten Datenpunkten trainiert. Der globale Markt für mobile medizinische Bildgebung, der 2023 einen Wert von 14,78 Milliarden Dollar hat, wird bis 2030 voraussichtlich 18,4 Milliarden Dollar erreichen.
- Received over $7.2M in non-dilutive government funding since 2018
- FDA Breakthrough Device Designation obtained in 2018
- AI system trained on 340 billion clinically validated data points
- Operating in a growing market projected to reach $18.4B by 2030
- None.
Insights
The DeepView SnapShot® M development represents a significant milestone in military medical diagnostics. The device's progress at Brooke Army Medical Center, backed by
The market opportunity is substantial, with the mobile medical imaging services sector projected to reach
Spectral AI is dedicated to supporting the U.S. Military, first responders, and healthcare providers in delivering life-saving diagnostics in the most critical environments.
DALLAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (Spectral AI or the Company), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced its DeepView SnapShot® M device continues to develop based upon preliminary feedback from its usability study with the Brooke Army Medical Center and the U.S. Army Medical Research and Development Command's Institute of Surgical Research. This milestone positions Spectral AI as a game-changer in wound care diagnostics, addressing significant unmet needs in diverse markets, including the U.S. Department of Defense, home healthcare, and emergency medical services.
Spectral AI plans to continue the design and development of the technology, which will involve rigorous testing and evaluation of the DeepView SnapShot® M's performance in various military and healthcare settings. The Company will provide regular updates as the development progresses, ensuring transparency and trust in the process. Spectral AI intends to launch DeepView SnapShot® M for military use upon completion.
DeepView SnapShot® M, with its AI-powered multispectral imaging, provides rapid and precise wound assessments, enabling better treatment decisions in the most challenging critical care environments. Its portability and ease of use make it uniquely suited for deployment in multiple scenarios, including combat zones and disaster response, where traditional diagnostic tools fall short.
The development of the DeepView SnapShot® M has been supported by a contract with the Defense Health Agency and the U.S. Army Medical Material Development Activity and from the Medical Technology Enterprise Consortium (MTEC) and the STTR program for more than
Spectral AI has received more than
Brooke Army Medical Center (BAMC) and the U.S. Army Medical Research and Development Command's Institute of Surgical Research has provided initial feedback on the preliminary design of the miniaturized device under the MTEC contract. This collaborative process will allow Spectral AI to continue to optimize the device's size, shape, and usability to meet the specifications required for military operations.
"DeepView SnapShot® M represents a breakthrough in medical imaging and diagnostics," said Dr. J. Michael DiMaio, Chairman of the Board at Spectral AI. "Its readiness for military applications is not only a testament to our commitment to innovation but also a source of immense pride and gratitude from everyone at Spectral AI. We are honored to support our nation's armed forces, emergency responders, and healthcare professionals with technology that can improve patient outcomes and make a meaningful difference in critical care environments."
Spectral AI's research and development team has continued to refine the device, incorporating features tailored to military use. Notable advancements include the miniaturization of the device’s five cameras while maintaining the same depth of wavelength capture as the cart-based DeepView System®. Despite its smaller size, the continued development will ensure there is no tradeoff in accuracy or tolerance. The cameras have also been optimized to reduce unwanted light, a critical feature for field-based imaging outside of clinically controlled environments.
DeepView AI®-Burn, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2018, utilizes multispectral imaging and AI algorithms to predict burn healing potential. The system provides clinicians with an immediate binary prediction of wound healing, guiding treatment decisions. Trained on over 340 billion clinically validated data points, it can distinguish between healing and non-healing tissue with unparalleled precision.
The addressable market for DeepView SnapShot® M is vast and growing. The global mobile medical imaging services market is experiencing significant growth, driven by the increasing demand for portable diagnostic solutions across various healthcare settings. In 2023, the market was valued at approximately USD 14.78 billion and is projected to reach USD 18.4 billion by 2030. DeepView SnapShot® M is designed for use in:
- Military Applications: Enhancing care for service members in combat and field hospitals.
- Home Healthcare: Supporting remote diagnostics for patients with chronic wounds.
- Ambulance Services: Improving pre-hospital decision-making in emergency wound care.
- Outpatient Clinics: Reducing time to treatment with real-time wound assessments.
For more information about Spectral AI and its technologies, including the DeepView SnapShot® M and the DeepView System, visit our website at www.spectral-ai.com.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize wound care management by "Seeing the Unknown®" with its DeepView System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight toward value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intention to separate its Spectral IP subsidiary from the Company, and each Company’s strategy, plans, objectives, initiatives, strategic goals, financial outlook or other non-historical matters. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Spectral AI undertakes no obligation to update any forward-looking statements except as otherwise required by law.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
What is the market size for Spectral AI's (MDAI) DeepView SnapShot® M device?
How much government funding has Spectral AI (MDAI) received for DeepView SnapShot® M?
When did Spectral AI (MDAI) receive FDA Breakthrough Device Designation for DeepView AI®-Burn?
How many data points is Spectral AI's (MDAI) DeepView system trained on?
